Skip to main content
. Author manuscript; available in PMC: 2014 Aug 22.
Published in final edited form as: Cytotherapy. 2013 Aug 28;15(11):1406–1415. doi: 10.1016/j.jcyt.2013.06.003

Figure 4.

Figure 4

In vitro activity of manufactured anti-CD19-CAR T cells. Anti-CD19-CAR transduced T cells (Panels A and C) generated from two different apheresis from the same B-cell CLL patient, VR2 (Panel A) and VR3 (Panel C), kill CD19+ ALL cell lines (NALM6, KOPN8, REH, SEM) and the positive control, K562-CD19, but not the CD19 negative targets, K562-NGFR. Percent cytotoxicity is shown at various effector-to-target (E:T) ratios. In contrast, cells prepared in similar manner but not transduced with the CAR have little non-specific cytotoxicity (Panels B and D, VR2 and VR3 respectively).